Aryl Amide S1P Analogues Resolving Hydrolysis and Selectivity Trade-offs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for Sphingosine 1-phosphate (S1P) analogs that can modulate activity across multiple S1P receptors, particularly S1P1 and S1P3, with enhanced selectivity and potency, and are resistant to hydrolysis in biological systems.
Innovation Solution
Development of ester or salt compounds covalently bonded to specific structures that act as antagonists at S1P1 and/or S1P3 receptors, including hydrolysis-resistant forms, which can be used to treat various medical conditions such as neoplastic diseases, autoimmune diseases, and cardiac arrhythmias.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If S1P analogs are designed to modulate multiple S1P receptors (S1P1 and S1P3), then receptor selectivity and potency are improved, but metabolic stability (resistance to hydrolysis) deteriorates
Solution Approach 1:
The patent modifies the chemical parameters of S1P analogs by replacing the hydrolyzable phosphate group with non-hydrolyzable isosters such as phosphonates, phosphinates, and phosphonothioates. These parameter changes maintain the ability to bind and modulate S1P1 and S1P3 receptors with high selectivity and potency while conferring resistance to phosphatase-mediated hydrolysis, thereby achieving both improved receptor selectivity and enhanced metabolic stability.
Solution Approach 2:
The patent creates composite molecular structures by combining the sphingosine backbone with various aryl amide substituents and non-hydrolyzable phosphate surrogates. These composite analogs integrate multiple functional elements that collectively provide both specific receptor modulation (S1P1 and S1P3 selectivity) and metabolic stability, resolving the contradiction between achieving high receptor selectivity and maintaining metabolic stability.
2Reliability
If S1P analogs are designed with high receptor selectivity for S1P1 and S1P3, then antagonist activity is improved, but susceptibility to phosphatase hydrolysis increases
Solution Approach 1:
The patent converts the harmful effect of phosphatase hydrolysis into a beneficial feature by designing analogs with non-hydrolyzable phosphate surrogates. The phosphonate, phosphinate, and phosphonothioate groups are specifically engineered to be resistant to phosphatase enzymes while maintaining the ability to function as S1P receptor antagonists. This transforms the vulnerability to hydrolysis into a protective feature that enhances in vivo stability and reliability of antagonist activity.
Solution Approach 2:
The patent changes the chemical parameters of the phosphate group by introducing carbon-phosphorus bonds (in phosphonates) or phosphorus-nitrogen bonds (in phosphinates) instead of the hydrolyzable phosphorus-oxygen bonds found in natural S1P. These parameter changes create bonds that are resistant to phosphatase hydrolysis while preserving the molecular geometry and electronic properties necessary for high-affinity binding to S1P1 and S1P3 receptors, thereby maintaining reliable antagonist activity.
3Reliability
If natural S1P structure is used, then metabolic stability is poor, but receptor binding capability is maintained
Solution Approach 1:
The patent introduces intermediary chemical structures (phosphonate, phosphinate, and phosphonothioate groups) that serve as non-hydrolyzable surrogates for the native phosphate group. These intermediaries maintain the essential binding interactions with S1P receptors while acting as protective substitutes that resist enzymatic degradation. The intermediary groups preserve the molecular features necessary for receptor binding capability while simultaneously providing enhanced metabolic stability.
Solution Approach 2:
The patent systematically changes the chemical parameters of the phosphate moiety by replacing P=O bonds with P=C bonds (phosphonates) or P-N bonds (phosphinates), and by introducing sulfur analogs (phosphonothioates). These parameter changes fundamentally alter the metabolic stability profile of the molecule without compromising the receptor binding capability, as the core sphingosine-aryl amide structure and key functional groups remain intact.
Data Source
AI summary
The present invention provides compounds that have antagonist activity at the S1P1 and/or S1P3 receptors. These compounds have enhanced selectivity and potency at the S1P1 and/or S1P3 receptors.